Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status

Publisher： Karger

E-ISSN： 2296-5262|36|11|670-673

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.11, 2013-10, pp. : 670-673

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 249-252

Karger

Access to resources Recommend Favorite

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer

By  

Case Reports in Oncology, Vol. 5, Iss. 2, 2012-08 ,pp. : 428-433

Karger

Access to resources Recommend Favorite

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 6, 2015-09 ,pp. : 1467-1474

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 150-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quality of life in patients with K‐RAS wild‐type colorectal cancer

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 181-189

John Wiley & Sons Inc

Access to resources Recommend Favorite